{"name":"The Lymphoma Academic Research Organisation","slug":"the-lymphoma-academic-research-organisation","ticker":"","exchange":"","domain":"lysarc.org","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-03-31","label":"Vindesin Phase 3 readout (ETP-ALL)","drug":"Vindesin","drugSlug":"vindesin","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-11-22","label":"Vindesin Phase 3 readout (Lymphoblastic Lymphoma, Childhood)","drug":"Vindesin","drugSlug":"vindesin","type":"phase3_readout","sentiment":"neutral"},{"date":"2031-12-01","label":"Vindesin Phase 3 readout (Lymphoblastic Lymphoma)","drug":"Vindesin","drugSlug":"vindesin","type":"phase3_readout","sentiment":"neutral"},{"date":"2032-11-01","label":"Vindesin Phase 3 readout (High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy)","drug":"Vindesin","drugSlug":"vindesin","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":9,"colorKey":"oncology","drugs":[{"name":"Rituximab - CHOP","genericName":"Rituximab - CHOP","slug":"rituximab-chop","indication":"B-cell non-Hodgkin lymphoma (in combination with CHOP chemotherapy)","status":"phase_3"},{"name":"Rituximab - CVP","genericName":"Rituximab - CVP","slug":"rituximab-cvp","indication":"B-cell non-Hodgkin lymphoma (in combination with CVP chemotherapy)","status":"phase_3"},{"name":"Vinblastin","genericName":"Vinblastin","slug":"vinblastin","indication":"Carcinoma of female breast","status":"marketed"},{"name":"Vindesin","genericName":"Vindesin","slug":"vindesin","indication":"Acute lymphoid leukemia","status":"discontinued"},{"name":"Brentuximab Vedotin - induction","genericName":"Brentuximab Vedotin - induction","slug":"brentuximab-vedotin-induction","indication":"Hodgkin lymphoma","status":"phase_2"},{"name":"Mosunetuzumab (SC)","genericName":"Mosunetuzumab (SC)","slug":"mosunetuzumab-sc","indication":"Relapsed or refractory B-cell non-Hodgkin lymphoma","status":"phase_3"},{"name":"R-CHOP / R-HAD","genericName":"R-CHOP / R-HAD","slug":"r-chop-r-had","indication":"Diffuse large B-cell lymphoma (DLBCL)","status":"phase_3"},{"name":"RCHOP21","genericName":"RCHOP21","slug":"rchop21","indication":"Follicular lymphoma","status":"phase_3"},{"name":"Romidepsin + CHOP","genericName":"Romidepsin + CHOP","slug":"romidepsin-chop","indication":"Peripheral T-cell lymphoma (PTCL)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Aracytine","genericName":"Aracytine","slug":"aracytine","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Rituximab - CHOP","genericName":"Rituximab - CHOP","slug":"rituximab-chop","phase":"phase_3","mechanism":"Rituximab is a monoclonal antibody that binds to CD20 on B cells and triggers their destruction, used in combination with CHOP chemotherapy to treat lymphomas.","indications":["B-cell non-Hodgkin lymphoma (in combination with CHOP chemotherapy)","Diffuse large B-cell lymphoma (DLBCL)"],"catalyst":""},{"name":"Rituximab - CVP","genericName":"Rituximab - CVP","slug":"rituximab-cvp","phase":"phase_3","mechanism":"Rituximab is a monoclonal antibody that binds to CD20 on B cells and triggers their destruction, combined with CVP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) to treat lymphoma.","indications":["B-cell non-Hodgkin lymphoma (in combination with CVP chemotherapy)","Diffuse large B-cell lymphoma"],"catalyst":""},{"name":"Vinblastin","genericName":"Vinblastin","slug":"vinblastin","phase":"marketed","mechanism":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1","indications":["Carcinoma of female breast","Gestational trophoblastic neoplasia","Hodgkin's disease","Kaposi's sarcoma","Langerhans cell histiocytosis, disseminated"],"catalyst":""},{"name":"Vindesin","genericName":"Vindesin","slug":"vindesin","phase":"discontinued","mechanism":"Cytochrome P450 3A4","indications":["Acute lymphoid leukemia","Chronic myeloid leukemia","Malignant melanoma","Malignant tumor of lung"],"catalyst":""},{"name":"Aracytine","genericName":"Aracytine","slug":"aracytine","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Brentuximab Vedotin - induction","genericName":"Brentuximab Vedotin - induction","slug":"brentuximab-vedotin-induction","phase":"phase_2","mechanism":"Brentuximab vedotin is a monoclonal antibody-drug conjugate that targets CD30, a protein often found on the surface of Hodgkin lymphoma and anaplastic large cell lymphoma cells.","indications":["Hodgkin lymphoma","Anaplastic large cell lymphoma"],"catalyst":""},{"name":"Mosunetuzumab (SC)","genericName":"Mosunetuzumab (SC)","slug":"mosunetuzumab-sc","phase":"phase_3","mechanism":"Mosunetuzumab is a bispecific antibody that simultaneously engages CD20 on B cells and CD3 on T cells to redirect T cell killing of B cell lymphomas.","indications":["Relapsed or refractory B-cell non-Hodgkin lymphoma","Follicular lymphoma"],"catalyst":""},{"name":"R-CHOP / R-HAD","genericName":"R-CHOP / R-HAD","slug":"r-chop-r-had","phase":"phase_3","mechanism":"R-CHOP/R-HAD is a combination chemotherapy regimen that uses rituximab (an anti-CD20 monoclonal antibody) plus alternating cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and HAD (high-dose cytarabine, doxorubicin, dexamethasone) to target B-cell lymphomas.","indications":["Diffuse large B-cell lymphoma (DLBCL)","Other aggressive B-cell non-Hodgkin lymphomas"],"catalyst":""},{"name":"RCHOP21","genericName":"RCHOP21","slug":"rchop21","phase":"phase_3","mechanism":"Rituximab targets and depletes CD20-positive B cells, while cyclophosphamide, doxorubicin, and prednisone work through various mechanisms to induce cell death in cancer cells.","indications":["Follicular lymphoma","Diffuse large B-cell lymphoma"],"catalyst":""},{"name":"Romidepsin + CHOP","genericName":"Romidepsin + CHOP","slug":"romidepsin-chop","phase":"phase_3","mechanism":"Romidepsin inhibits histone deacetylases to promote cancer cell death, combined with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) for multi-modal lymphoma treatment.","indications":["Peripheral T-cell lymphoma (PTCL)","Cutaneous T-cell lymphoma (CTCL)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOUDJBVGw1aE9RcVdzLTZnOUZEbGxESnZkWExES0hBWHJ5TXFwcHc3VncwSVlJVm42dThJTzRqMHlNV29SSGRUdUJfUTVNT3R5R1JCTnFGbmdfcG95cTZiQ3JRdzl0UlNXYTZ6ZW5oOEE1OW9jcVFxTU80QkRib3p5M1BJa0lpX2o5Ul96NzhZTjd2Z21sak11ckx5aUJvcENPWlE?oc=5","date":"2026-02-10","type":"trial","source":"KFF Health News","summary":"US Cancer Institute Studying Ivermectin’s ‘Ability To Kill Cancer Cells’ - KFF Health News","headline":"US Cancer Institute Studying Ivermectin’s ‘Ability To Kill Cancer Cells’","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AJBVV95cUxQZ2s1YTR4eUk5M2VORlZhbEdIaWVFV1dWM0h4RXI4N3ZOcG15RXptMHZaM3kzdXdoN0YteENncmJVdWt0SFhKSkNmbkVoVUxsUlJJQm0xQVQyT3dBVXdoRXl3UjNfTFY4NExnc3dhQ0VBNk5qLU1xYktVNk9nS1BIREtOemFoRnc2Tm5pRk9RN2RpU3NnVzdoVllJQUdUVm1rN3BCYTZyd2xrSHF6MW9xM0VqV0RQeXczMFV3eVU4eVdjNkRnYUNSRTZJeGRWSllHVC1BdGRGZzVpamxXRVpNQi0tT3E1czVPTXhRaTVTZ01tLXkyanhCTnpiRHhWODRzOUF1aVFXbzNNc250Y04yY0x3Wlc0dG1CLURNSElpVEJSdmRuU1Bob3c2aVVCQVcyQUgxczhNY2VqcVhpZlFPa3YyclNZU2RPQlRGeWVqNmQ?oc=5","date":"2025-06-19","type":"pipeline","source":"PR Newswire","summary":"RWJBarnabas Health, Rutgers Cancer Institute, Tufts Medical Center, and The University of Manchester Develop First Risk Prediction Model for Early-Stage Classic Hodgkin's Lymphoma - PR Newswire","headline":"RWJBarnabas Health, Rutgers Cancer Institute, Tufts Medical Center, and The University of Manchester Develop First Risk ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1oY2dHUENlQ0doWnB6LUcwWmVjT3pLREh3elVCZGUwYW5NMlNRTE1uNF9CMzIycDdqaEtQY055RDN6R0d2aFgyTmN3WUhHbzI2eHBBNDAxcmVoQXdzUk9n?oc=5","date":"2025-04-24","type":"trial","source":"nature.com","summary":"Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study - nature.com","headline":"Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE5HMlpBa2lyMUYyWWJXSTNtSTNYSE51WkhuVG8tRUxWX0xZNWFHYVljVEFaNHJiOFVha1h1Rm9RRFBMU0xxRGNzaUhybFhpZ3dyOEFTejRJZ3phalE0MDIxTVo5VU5qd1J2QzIwMGh3ajc5S1ND?oc=5","date":"2025-02-26","type":"pipeline","source":"National Cancer Institute (.gov)","summary":"CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers - National Cancer Institute (.gov)","headline":"CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers - National Cancer Institute (.gov)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQS1AydS1Qbml3T1JfVlFGODI2Uk9NSWRwUmRtdnJEUUgyTHVzcHZobklXUzZvMm1IUTdfSERaTFAtbFB5bFBtMEhZT1RfemNBTXVCZ0x0eWtEMjlyamJ4QXN2TXNTaFpZUURUOVBVejVmVTZQUUxKUWtkY2w0ZnNVdndrY3VYX05GNWJPVTEtMkQ0a0QxSWFpTGYzckdOWjlNSk8tWVE2SnhFbGFvN0RhcQ?oc=5","date":"2024-07-31","type":"pipeline","source":"The Pharmaceutical Journal","summary":"Pharmaceuticals from marine sources: past, present and future - The Pharmaceutical Journal","headline":"Pharmaceuticals from marine sources: past, present and future","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNSE5MNEhpZm5jb1loNXdtUEZrNzJmdy14eEVhQWs1V2I3dk1kdktLa2lFTHNQVEp5dWExWXJrYXlfSmE0WFlYakRoZV9WZXJHRExCLWhkWC1IZ041TS1OeGE5V1ZoY205NGVKTzViNnhBUF9DMkFhanlEa013Z2NLLVBLamltckZOZTVzU1J6bElSZ293aHg3S1Y1TlZlejFUQmREN2lwa0hYZTVC?oc=5","date":"2024-07-09","type":"regulatory","source":"Stanford Medicine","summary":"Trial of cell-based therapy for high-risk lymphoma leads to FDA breakthrough designation - Stanford Medicine","headline":"Trial of cell-based therapy for high-risk lymphoma leads to FDA breakthrough designation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQc2Z1OUFlTDNVcndpODk5SkJFZnoyR1o5V1ZXU1NNclZkeWE0ZVZ6ZTJZcDdiVTczVHJyelRKMjFtYXFheWFQSEdQbXJXVi1fZUdKeXJucHk2ZEVnZGZQek5PbHdDMTBjS2EyQ1BldUl2RmFPb3hlX0JaRzV0YnJqN1p6Q1d6S1VrZ2U2NlMxY2RKZS0zYkxBSnR0THhUaGFXV3huQlB3UnB4ZDZQ?oc=5","date":"2022-01-20","type":"deal","source":"Veeva","summary":"LYSARC Partners with Veeva to Accelerate Innovation for Lymphoma Treatments - Veeva","headline":"LYSARC Partners with Veeva to Accelerate Innovation for Lymphoma Treatments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1rNEc2UURsSDFtbnM2RFd2Z2ZRUVE2RmVsbWo5ZFpMbTE2WnQxQzBHN1BacmRtams3TGdtV01fWnBvbzNUaXE3TGcycEJFSjEzQWJrbnZsZkY4VWI4M1p6OHhxVVhLVDI2WFB5cU5R0gFyQVVfeXFMTmI4YTFGdVFTQTk2X2hkTmNGejIzUTZoNDVTM2NkWDFabGdCb0tlUExHcUw3a0tyaU42VWh4M2o5SDZLcGtuM1NkWmRabWJQM05HYWVWSUFHQVNCM28zcmV1dTdZeUwyQWdfZTBwZ0tTcXlB?oc=5","date":"2021-12-14","type":"pipeline","source":"koreabiomed.com","summary":"Novartis reduces CAR-T manufacturing time to 2 days - koreabiomed.com","headline":"Novartis reduces CAR-T manufacturing time to 2 days","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AJBVV95cUxNcTRSWmtFOFk1WXBBZjFVLWxEYkVhZWdYOWhfZnpNTkFpTFFZaGY1eDhjS1kwcWdKQkNodlJEcHJ2NzgtWi13S29mNXVtWlU5ZERQOVdGNnJ5RnZwUXBfeENjLUxEVjJrZThxNjhoR0FIQ05RZWVqWFBZbTUzaW9lU2tndWQ5SGdMSWpFbU5hdGJhV0FQLWdndDFiZXNBNHdUQ1N4VmhWaFFNRDM5VVc1SWJGX2FSaUVhWjRaOVVXSmcwdU1kYi1HUlowbnY4VUJSSXVSeGJOZERNMjREQV91NFBqRk9Eb0psd2JYcVJzdFphZ1cwRWV2eXdVV0dfTlprQXRLODRkMlA1QmppNmdxZkRkMEQxWTIwMnB4anJySTlGQTlxRXBIeWVCNV90bzN2d1FBRGg4M2lpRXJjeTQ1Mi05Z3ZzUEhXMDQ4bG5zWHpDWFQtWm5QSjVoMEFieldV?oc=5","date":"2020-05-14","type":"pipeline","source":"European Medical Journal","summary":"Highlights of the European Organisation for Research and Treatment of Cancer-Cutaneous Lymphoma Task Force (EORTC-CLTF) Annual Congress 2019 (Athens, Sept 26-28): Experiences with Chlormethine Gel in ","headline":"Highlights of the European Organisation for Research and Treatment of Cancer-Cutaneous Lymphoma Task Force (EORTC-CLTF) ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQVXBsU2VXdjgwVmx2QUhFei1nLXlEY3kxamFydUlObE4xSU5vODZDc1pKekJaUDBpMWtxcmZFNGduTVhkdXNmdDJZUXVJTHhJRzNCWllSWllvODZEamUzdDhlc1V5MHFNdUdkQVRISURGWWZaRWw0VlNrUjU4b3Y1T1pIdUxmTEE?oc=5","date":"2018-09-10","type":"pipeline","source":"Pharmaceutical Technology","summary":"Blood Cancer Awareness Month UK: revolutionary treatments upcoming - Pharmaceutical Technology","headline":"Blood Cancer Awareness Month UK: revolutionary treatments upcoming","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE9LaEhCVmVlZFlOWkFQTFVqbGIwbkZQVHdoMHFLaGhIR0JOSkx6NGpLMnhHLVUxdnBKRFdBOUQ4aFlZUXlrMXBxajI3WUEzX0FWdGNxR3lldnQ4TzdkZ1FLaWR4ZlVoQUIyZlZDY2g1dVRUallZLW5Pa0R3?oc=5","date":"2015-12-15","type":"pipeline","source":"statnews.com","summary":"From the ivory tower to the corner office, academics infuse new life into pharma - statnews.com","headline":"From the ivory tower to the corner office, academics infuse new life into pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPLWctOUFRQW55TUVaTnFkYlVZTUpNaGhLc3AwbzVEQzlocDg5eDFGeERYMTg4bUNtam44cFp4eU1DSHRLVk8wc0N2cmY4djRrNW9DNUM2X0RucjdFUmhVVXdsTWw0Zm9URExobXI3eDI3RFVVc0ZHT295TWs3NW41SGpmVjBqblB4LThqR0lzT2h0Zk9OVnlJSEJLSTVpckVZcWVPZExHSDJuTTc2UXJRVzhKQ1NLejh2dFZteg?oc=5","date":"2014-11-19","type":"deal","source":"The New York Times","summary":"Deal by Cystic Fibrosis Foundation Raises Cash and Some Concern (Published 2014) - The New York Times","headline":"Deal by Cystic Fibrosis Foundation Raises Cash and Some Concern (Published 2014)","sentiment":"neutral"}],"patents":[],"drugCount":10,"phaseCounts":{"phase_3":6,"marketed":1,"discontinued":1,"phase_2":2},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}